article thumbnail

FDA $7bn plans for 2024: disclose contract manufacturers, restart Cancer Moonshot

Pharmaceutical Technology

The US FDA has revealed its detailed budget proposal for FY2024, which would require pharma companies to name their active pharmaceutical ingredient (API) suppliers, restart President Biden’s Cancer Moonshot, inject cash into amyotrophic lateral sclerosis (ALS) research, and enforce stricter rules around manufacturing, recalls, and shortages.

article thumbnail

Nanoparticles: Emerging Stars for Pharmaceutical Industry

Roots Analysis

Role of nanoparticles has been well established across various markets, such as healthcare, paint, consumer products ( including sunscreens, cosmetics ), aerospace and glass industries. Hence, many pharmaceutical companies outsource manufacturing of nanoparticles to third party organizations, called as contract manufacturers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Issues Draft Guidance on Registration and Listing for Cosmetics Required under MOCRA

FDA Law Blog

As reported previously , MOCRA includes a requirement for facility registration and listing of cosmetic products. Specifically, with some exceptions, parties that own or operate a facility engaged in the manufacturing or processing of a cosmetic product for distribution in the United States must list their facilities.

article thumbnail

List of Top 10 Pharma Franchise Companies in India

Fossil Remedies

150+ Skin & Cosmetic Products. Wellona Pharma is a leading WHO , GMP certified manufacturer of pharmaceutical & healthcare products and well established name in the field as an exporter and supplier of pharmaceutical finished formulation products across the globe. They offer pharma franchise to interested parties.

article thumbnail

FDA End-of-Year Release of Warning Letters Impresses (or Depresses)

FDA Law Blog

The letter also stated that the company’s response to the inspection report was “inadequate because it did not include a review of environmental monitoring data in your manufacturing areas, an adequate risk analysis of previously manufactured drug product, or testing of reserve samples from impacted batches.” Patcos Cosmetics Pvt.